- Report
- February 2024
- 120 Pages
Asia Pacific
From €4756EUR$4,950USD£4,090GBP
- Report
- April 2024
- 1800 Pages
Global
From €3839EUR$3,995USD£3,301GBP
- Report
- May 2024
- 450 Pages
Global
From €3839EUR$3,995USD£3,301GBP
- Report
- August 2023
- 285 Pages
Global
From €4756EUR$4,950USD£4,090GBP
- Report
- January 2024
- 200 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Report
- February 2024
- 150 Pages
Global
From €5717EUR$5,950USD£4,916GBP
- Report
- March 2024
- 194 Pages
Global
From €3242EUR$3,374USD£2,788GBP
€3602EUR$3,749USD£3,097GBP
- Report
- May 2024
- 193 Pages
Global
From €4756EUR$4,950USD£4,090GBP
- Report
- August 2023
- 150 Pages
Global
From €5717EUR$5,950USD£4,916GBP
- Report
- May 2024
- 92 Pages
Global
From €5381EUR$5,600USD£4,627GBP
- Report
- February 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Report
- January 2024
- 200 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Report
- January 2024
- 200 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Report
- January 2024
- 150 Pages
Global
From €4660EUR$4,850USD£4,007GBP
- Report
- September 2023
- 190 Pages
Global
From €2393EUR$2,490USD£2,057GBP
- Report
- January 2024
- 181 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- October 2023
- 183 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- November 2023
- 630 Pages
Global
From €9128EUR$9,500USD£7,849GBP
- Report
- October 2023
- 181 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- October 2023
- 180 Pages
Global
From €4708EUR$4,900USD£4,048GBP
Lymphoma is a type of hematological malignancy that originates in the lymphatic system. It is characterized by the uncontrolled growth of lymphocytes, a type of white blood cell. Lymphomas can be either Hodgkin's or non-Hodgkin's, and can be either indolent or aggressive. Treatment options for lymphoma include chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies.
The lymphoma market is a subset of the larger hematology market, which includes treatments for a variety of blood-related diseases. The lymphoma market is driven by the increasing prevalence of the disease, as well as the development of new treatments.
Companies in the lymphoma market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Novartis, and Pfizer. Show Less Read more